

Closing Remarks

Michael A. Mussallem
Chairman and CEO



Edwards

Patient-Focused Innovation Strategy



Innovation

Pioneer breakthrough technologies with compelling evidence

Leadership

Lead groundbreaking standards of care through trusted relationships

Focus

Singular focus on the large unmet needs of structural heart and critically ill patients

Create Meaningful Value by Transforming Patient Care

2022 expected to be a year of significant milestone achievements and investment in our future



TAVR

Moderate AS trial enrollment
SAPIEN X4 trial enrollment



TMTT

PASCAL - DMR approval in the U.S.
EVOQUE TR approval in Europe



SURGICAL

MITRIS approval in the U.S.
Continued adoption of RESILIA



CRITICAL CARE

HemoSphere with Viewfinder
Smart BP enrollment

Low double-digits
Underlying sales growth

2022
EXPECTATIONS

\$2.50 - \$2.65
Adjusted EPS

Edwards' Board is accomplished and engaged



Leading governance practices



Highly experienced leaders



Oversees compensation program based on performance:

- Financial performance
- Key operating drivers
- Shareholder value creation

Sustainability is integrated into our culture and strategy



Edwards is committed to giving back

Foundation supporting 250+ global charities in 2021



Every Heartbeat Matters

Improve the lives of **2.5M** additional underserved structural heart and critical care patients by the end of 2025



Strengthening Our Communities

Meet basic community needs where we live and work; **>80%** employee involvement towards our 100% aspiration

Edwards is poised for long-term value creation

Large Populations

of patients with unmet needs



Patient-Focused Culture

motivates and guides our global team



Credibility and Trust

with clinicians, regulators,
payors and patients



Innovative R&D

produces breakthrough therapies
and drives shareholder returns



Sustainable

organic long-term sales growth



We are just getting started



Edwards

Helping Patients is Our Life's Work, and
life is now